The first vaccines developed to prevent code 19 from the new corona virus may not be ideal and will not work for everyone.
Kate Bingham, chairman of the UK’s Vaccine Task Force, made the warning in an article.
He said that no other vaccine in the history of medicine had such high expectations and now vaccination is being considered as the only strategy to eradicate the epidemic.
Read More:Volunteer dies during coronavirus vaccine trial in Brazil
However, citing such high expectations, he warned that a single vaccine may not be effective for everyone or may not be effective for a very long time.
“We don’t know if we will be able to get a vaccine, so it’s important not to be satisfied with that idea and too much expectation,” he wrote in an article in the medical journal Lancet.
He added: “Early vaccines may not be ideal and there is a need to be prepared so that they do not prevent the disease, but only reduce the symptoms, and may even be longer for everyone.” Not even effective.
The task force was set up on the advice of Sir Patrick Wells, the British government’s chief scientific adviser.
Kate Bingham wrote in her paper that a strategy has been put in place to increase the chances of a safe and vaccine supply to the UK, but also to keep in mind that the first vaccines may have failed to prevent an epidemic. Will be
British Foreign Secretary George Iowa said Kate Bingham’s analysis was “probably correct”.
“It’s too early to say about a vaccine that will be ready by then. I know there are expectations that there could be some kind of breakthrough by the end of the year, but there is no guarantee,” he told Sky News. no’.
It is believed that more than 200 vaccines are being developed worldwide, of which 44 are undergoing clinical trials.
Read More:China’s experimental Corona vaccine declared safe in third phase
Nine of the 44 trials have entered the third phase, confirming the efficacy and safety of vaccines in thousands of people.
Earlier this month, medical experts suggested that an effective vaccine against the corona virus would not be available to the general public until the fourth quarter of 2021.
This was revealed in a medical study conducted in Canada in which experts from the field of vaccine development were consulted.
The McGill University survey looked at 28 experts in the field of vaccineology.
The study began in late June and most of the experts involved were from Canada or the United States who have been active in their field for an average of 25 years.
Researcher Jonathan Camilleman said that the experts in our survey, in their predictions about the availability of the vaccine, made it very unlikely that any corona vaccine would be available to the public in early 2021.
In fact, most believed that the availability of the vaccine by the summer of next year would be part of the best scenario.
Many experts believe that before the availability of an effective vaccine, there may be some kind of bad start.
According to the study, experts believe that there is a one-third chance that a safety warning may be issued for the vaccine after approval, while there is a 40 percent chance that the first large-scale study will report the efficacy.
Read More:The potential cost of the soon to be available corona vaccine has been revealed
The study also found that one-third of experts believed that the following barriers to vaccine development could be encountered:
1. The first vaccine to be developed in the United States and Canada could be warned by the FDA that it could have deadly side effects or
2. This first large-scale trial will not say anything about the usefulness or will have negative consequences.
“Our research has found that experts agree on the duration of the corona virus vaccine’s availability,” the researchers said.
“Although experts’ opinions do not match the government’s welcome estimates, they reflect the view that researchers will complete their work much faster this time around than in previous vaccines,” he said.